FierceBiotech Radio on the burning hole in Gilead's $25B pocket and AbbVie's future in hematology

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a consideration of how a certain biotech entrepreneur is bringing attention to an FDA loophole.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to radio@fiercebiotech.com.

Read more on